A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis.
We have tested a new ligand for peroxisome proliferator-activated receptor-gamma, GW7845, as an inhibitor of experimental mammary carcinogenesis, using the classic rat model with nitrosomethylurea as carcinogen. Rats were first treated with a single dose of nitrosomethylurea (50 mg/kg body weight, i.p.). Starting 1 week later, they were fed GW7845, at either 60 or 30 mg/kg of diet, for 2 months. This agent significantly reduced tumor incidence, tumor number, and tumor weight at both doses. This is the first report of the use of a ligand for peroxisome proliferator-activated receptor-gamma to prevent experimental breast cancer.
Suh
N
N
Department of Pharmacology and Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, New Hampshire 03755, USA.
Wang
Y
Y
Williams
C R
CR
Risingsong
R
R
Gilmer
T
T
Willson
T M
TM
Sporn
M B
MB
D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D002273:Carcinogens; D004354:Drug Screening Assays, Antitumor; D005260:Female; D008024:Ligands; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000517:prevention & control*; D008770:Methylnitrosourea; D010080:Oxazoles / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism*; D013629:Tamoxifen / Q000627:therapeutic use; D014157:Transcription Factors / Q000378:metabolism*; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D016588:Anticarcinogenic Agents; D002273:Carcinogens; D008024:Ligands; D010080:Oxazoles; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors; D013629:Tamoxifen; C401311:GW 7845; D014443:Tyrosine; D008770:Methylnitrosourea